Document Detail

A comparison of free autologous breast reconstruction with and without the use of laser-assisted indocyanine green angiography: a cost-effectiveness analysis.
MedLine Citation:
PMID:  23629108     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Laser-assisted indocyanine green angiography is a U.S. Food and Drug Administration-approved technology used to assess tissue viability and perfusion. Its use in plastic and reconstructive surgery to assess flap perfusion in autologous breast reconstruction is relatively new. There have been no previous studies evaluating the cost-effectiveness of this new technology compared with the current practice of clinical judgment in evaluating tissue perfusion and viability in free autologous breast reconstruction in patients who have undergone mastectomy.
METHODS: A comprehensive literature review was performed to identify the complication rate of the most common complications with and without laser-assisted indocyanine green angiography in free autologous breast reconstruction after mastectomy. These probabilities were combined with Medicare Current Procedural Terminology provider reimbursement codes (cost) and utility estimates for common complications from a survey of 10 plastic surgeons to fit into a decision model to evaluate the cost-effectiveness of laser-assisted indocyanine green angiography.
RESULTS: The decision model revealed a baseline cost difference of $773.66 and a 0.22 difference in the quality-adjusted life-years, yielding an incremental cost-utility ratio of $3516.64 per quality-adjusted life year favoring laser-assisted indocyanine green angiography. Sensitivity analysis showed that using laser-assisted indocyanine green angiography was more cost-effective when the complication rate without using laser-assisted indocyanine green angiography (clinical judgment alone) was 4 percent or higher.
CONCLUSIONS: The authors' study demonstrates that laser-assisted indocyanine green angiography is a cost-effective technology under the most stringent acceptable thresholds when used in immediate free autologous breast reconstruction.
Abhishek Chatterjee; Naveen M Krishnan; Michael M Van Vliet; Stephen G Powell; Joseph M Rosen; Emily B Ridgway
Related Documents :
23012298 - Imaging of triple-negative breast cancer.
23218708 - Defining biomarkers to predict sensitivity to pi3k/akt/mtor pathway inhibitors in breas...
24084878 - Barbed sutures in breast reconstruction.
25015158 - Optimizing prostate specimen handling for diagnosis and prognosis.
1621308 - Radiation therapy in prostate cancer: whole pelvis with prostate boost or small field t...
22194518 - Results of a multicenter patient registry to determine the clinical impact of breast-sp...
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  Plastic and reconstructive surgery     Volume:  131     ISSN:  1529-4242     ISO Abbreviation:  Plast. Reconstr. Surg.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-30     Completed Date:  2013-07-16     Revised Date:  2014-10-13    
Medline Journal Info:
Nlm Unique ID:  1306050     Medline TA:  Plast Reconstr Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  693e-701e     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiography / economics*,  methods*
Coloring Agents / diagnostic use
Cost-Benefit Analysis
Free Tissue Flaps / blood supply,  economics
Health Care Surveys
Indocyanine Green / diagnostic use*
Mammaplasty / adverse effects,  economics*,  methods*
Postoperative Complications / economics,  prevention & control
Reg. No./Substance:
0/Coloring Agents; IX6J1063HV/Indocyanine Green

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Free tissue transfer in the obese patient: an outcome and cost analysis in 1258 consecutive abdomina...
Next Document:  A monitoring tool for performance improvement in plastic surgery at the individual level.